Performance Highlights:
- During the reporting period, the revenue was RMB 43.952 billion, with a
year-on-year growth of 12.66%; the net profit after
deducting extraordinary gain or loss attributable to owners of the
parent was RMB 3.873 billion, with a
year-on-year growth of 18.17%;
- The revenue from new products and sub-new products
including Han Li Kang,
Han Qu You, Comirnaty, Jie Bei An, Su Ke
Xin, Han Si Zhuang accounted
for more than 30% of the revenue from the pharmaceutical
manufacturing segment, and the revenue structure continued to be
optimized;
- The revenue in regions outside the Chinese Mainland and
other countries was RMB 13.938 billion, accounting for
31.71%, and the global operation capability was further
improved.
SHANGHAI, March 28,
2023 /PRNewswire/ -- On March 27, 2023, Shanghai Fosun Pharmaceutical
(Group) Co., Ltd.* ("Fosun Pharma" or "the Group", Stock
Code: 600196.SH; 02196.HK), a global innovation-driven
pharmaceutical and healthcare industry group deep-rooted in
China, announced its 2022 annual
results today (the "Reporting Period").
During the Reporting Period, Fosun Pharma achieved steady
business growth, mainly driven by the revenue growth from new
and sub-new products and the effective control of sales expenses.
In 2022, Fosun Pharma achieved a revenue of RMB 43.952 billion, with a year-on-year growth of
12.66%; the net profit after deducting extraordinary gain or loss
attributable to shareholders of the listed company was RMB 3.873 billion, with a year-on-year growth of
18.17%; the net cash flow from operating activities was
RMB 4.218 billion, with a
year-on-year growth of 7.1%. The Company has achieved remarkable
results in R&D innovation and transformation, and the
international operation capability was further improved to achieve
long-term sustainable development.
Continuously Increased R&D Investment with Remarkable
Results in Innovation and Transformation
Fosun Pharma is a patient-centered, clinical demand-oriented,
and innovative R&D driven company. Through independent R&D,
cooperative development, licensing introduction, and in-depth
incubation, Fosun Pharma continued to enrich innovative product
pipelines, improved the research and clinical development ability
of FIC (First-in-class) and BIC (Best-in-class) drugs, and
accelerated the research, development, and transformation of
innovative technologies and products.
Focusing on core therapeutic areas such as tumors (solid tumors
and hematologic tumors), immunology, central nervous system, and
chronic diseases (liver disease/metabolism/kidney disease), Fosun
Pharma continued to increase its investment in innovative R&D,
with a total R&D expenditure of RMB
5.885 billion for the year, with a year-on-year growth of
18.22%, among which, the R&D expenses amounted to RMB 4.302 billion, with a year-on-year growth of
RMB 0.465 billion or 12.12%. The
R&D expenditures in the pharmaceutical
manufacturing business amounted to RMB
5.097 billion, with a year-on-year growth of 13.62%, and the
R&D expenditures in the pharmaceutical manufacturing business
accounted for 16.54% of the revenue from the pharmaceutical
manufacturing business, among which, the R&D expenses amounted
to RMB 3.552 billion, accounting for
11.53% of the revenue from the pharmaceutical manufacturing
business.
During the reporting period, 6 self-developed innovative drugs
(indications), 4 license-in innovative drugs (indications), and 27
generic drugs (indications) of Fosun Pharma were approved for
launch in Chinese Mainland/Hong Kong,
China/United States; 7
innovative drugs (indications) and 30 generic drugs (indications)
had applied for launch (NDA) in Chinese Mainland; and 22 innovative
drugs (indications) were approved for clinical trials (IND) in
Chinese Mainland.
In 2022, multiple innovative products and indications of Fosun
Pharma were approved for launch, benefiting more patients
worldwide. Among them, Fosun Pharma's first self-developed
biopharmaceutical innovative drug, Han Si
Zhuang (Serplulimab Injection), has been successively
approved for three indications, Microsatellite Instability-high
(MSI-H) solid tumors, Squamous Non-small Cell Lung Cancer
(sqNSCLC) and Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in
Chinese Mainland; the indication of Small Cell Lung Cancer (SCLC)
was granted with Orphan Drug Designation by the U.S. FDA and the
European Commission (EC). The innovative indication Rheumatoid
Arthritis (RA) of Han Li Kang
(Rituximab injection) has been approved for launch and included in
the 2022 National Reimbursement Drug List.
Both the monovalent COVID-19 vaccine COMIRNATY (30 mg per dose)
(also known as BNT162b2 or COMIRNATY Original) and COMIRNATY
Original/Omicron BA.4/BA.5 bivalent COVID-19 vaccine (also known as
COMIRNATY Bivalent COVID-19 Vaccine) were officially registered in
Hong Kong SAR and approved as a regular imported vaccine by the
Macao SAR. The related dosage forms for children and infants have
also been granted the Emergency Use Authorization (EUA) in Hong
Kong SAR and Macao SAR, respectively, and included in the local
immunization programs; Azvudine Tablets jointly developed by Fosun
Pharma and Genuine Biotech obtained the emergency use authorization
from the National Medical Products Administration in July 2022 for use in the treatment of adult
COVID-19 patients with moderate symptoms.
Keverprazan Hydrochloride Tablets (trade name: Bei Wen), the first potassium ion competitive
acid blocker (P-CAB) independently developed in China, jointly developed by the Group and
Carephar and exclusively commercialized by the Group, was approved
for launch in Chinese Mainland in February
2023 for the treatment of duodenal ulcer (DU) and reflux
esophagitis (RE); Han Qu You
(Trastuzumab for Injection), independently developed by Fosun
Pharma and licensed to Cipla, has been approved for launch in
Australia, and its approved
indications cover all approved indications of the branded drug in
the local market.
As the first CAR-T cell therapy product approved for domestic
launch, Yi Kai Da (ejilunsai injection) from Fosun Kite, the cell
therapy platform of Fosun Pharma, was further improved in drug
accessibility. As of the end of 2022, Yi Kai Da has been included
in the urban customized commercial health insurance of 70 provinces
and municipalities and over 60 commercial insurances, while the
number of treatment centers on record ~exceeded 130. As of the end
of January 2023, nearly 300 patients
with relapsed or refractory large B-cell lymphoma lymphoma had been
treated with Yi Kai Da.
As of the end of the Reporting Period, the revenue from new
and sub-new products accounted for more than 30% of the revenue
from the pharmaceutical manufacturing business, which is mainly due
to the revenue contribution of newly launched products, namely
Han Si Zhuang and Jie Bei An, as well as the growth contribution
of sub-new products, namely Han Qu
You and Su Ke Xin,
promoting the sustained and steady growth of business.
Adhered to Globalization with Continuously Improvement in
Global Operation Capability
Relying on years of industrial experience, investment in
innovative R&D and expanding of global channel network, Fosun
Pharma has the industry-leading global two-way licensing capability
to maximize the value of self-developed products and cooperative
innovative products. During the Reporting Period, Fosun Pharma's
revenue outside the Chinese Mainland and other countries amounted
to RMB 13.938 billion, accounting for
31.71%.
In 2022, Fosun Pharma and Amgen's subsidiary formed
collaboration on the exclusive licensing to commercialize two
innovative drugs, namely Otezla® (Apremilast Tablets)
and Parsabiv (Etelcalcetide) in Chinese Mainland (excluding Hong
Kong SAR, Macao SAR, and Taiwan
region), further enriching Fosun Pharma's innovative product layout
in the non-tumor field; Shanghai Henlius, a subsidiary,
successively granted a number of product licenses to Getz Pharma,
Eurofarma, Abbott, Organon, and other companies in order to cover
the incremental markets with the help of international leading
partners. In addition, Gland Pharma, a subsidiary, proposed to
acquire Cenexi, a European CDMO company, with a maximum total
amount payable of up to EUR210
million, so as to strategically lay out its CDMO business in
the European market and construct localized manufacturing capacity
in Europe.
Fosun Pharma has taken the United
States as a breakthrough in overseas markets, actively
promoted the launch of generic drugs and Han Si Zhuang (Serplulimab Injection), and
continuously improved the commercialization capacity in the U.S.
market. At the same time, Tridem Pharma and Gland Pharma have
established their own sales teams in Africa and India respectively, and will further improve
the promotion and sales of products in other emerging markets in
the future.
Continuous R&D Innovation for the Benefit of the Public
and Active Practice of Social Responsibility
R&D innovation is the most important responsibility for
Fosun Pharma's sustainable development. Over the years, Fosun
Pharma has adhered to R&D innovation, with a number of
innovative achievements continuously implemented and a number of
innovative drugs and new indications included in the latest version
of the National Medical Insurance Drug Catalogue, further improving
the accessibility and affordability of innovative drugs and
benefiting more patients in China.
At the same time, Fosun Pharma has also given full play to its
own advantages and vigorously promoted the construction of basic
medical and health systems in developing countries and
underdeveloped areas to help solve the problem of drug
accessibility. In 2022, a subsidiary of Fosun Pharma was licensed
under MPP to produce and supply two high-quality and affordable
oral COVID-19 drugs to low- and middle-income countries in the
globally agreed regions; as of the end of 2022, Fosun Pharma's
Artesun® (Artesunate for Injection), a
self-developed antimalarial innovative drug, was adopted to treat
more than 56 million severe cases of malaria worldwide.
Fosun Pharma received many awards for its outstanding
performance in ESG management, social responsibility, and other
sustainable development fields. In 2022, Fosun Pharma was upgraded
to A level in the ESG rating published by MSCI, an international
index authority. Fosun Pharma has released CSR reports for 15
consecutive years to show stakeholders its practices and
achievements in the field of social responsibility. Experts of the
rating team of the China CSR Report Rating Expert Committee are of
the view that Fosun Pharma's CSR report is excellent and has
awarded the Company with a five-star rating.
"Looking forward to the future, Fosun Pharma will adhere to the
mission of promoting human health, and the business philosophy of
'Innovation for Good Health', guided by the '4IN' (Innovation,
Internationalization, Intelligentization, Integration) strategy."
Mr. Wu Yifang, Chairman of Fosun Pharma said, "Driven by the
rapid growth of the vast pharmaceutical market in China, the mainstream markets in Europe and the
United States, and some emerging markets, the Company will
adhere to the development strategy of 'Innovation Transformation,
Integrated Operation and Steady Growth' in the belief of creating
value for shareholders, continuously strengthen independent R&D
and external collaboration, enrich product pipelines, strengthen
global layout, and improve operational efficiency. In the process
of pursuing sustainable development, Fosun Pharma will make greater
contributions to the construction of a healthy China and the improvd health and well-being of
people worldwide."
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co.,
Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a
global innovation-driven pharmaceutical and healthcare industry
group deep-rooted in China. Fosun
Pharma directly operates businesses including pharmaceutical
manufacturing, medical devices, medical diagnosis, and healthcare
services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma
expands its areas in the pharmaceutical distribution and retail
business.
Fosun Pharma is patient-centered and clinical needs-oriented.
The company continuously enriches its innovative product pipeline
through independent research and development, cooperative
development, license-in, and in-depth incubation. Fosun Pharma
improves the research and clinical development capabilities of FIC
(First-in-class) and BIC (Best-in-class) new drugs as well as
accelerates the R&D and launch of innovative technologies and
products.
Guided by the 4IN strategy (Innovation, Internationalization,
Intelligentization, and Integration), Fosun Pharma will uphold the
development model of "Innovation Transformation, Integrated
Operation and Steady Growth", with the mission of creating
shareholder values through strengthening its independent R&D
and external cooperation and enriching its product pipelines, as
well as promoting the global networks and enhancing operational
efficiency. Fosun Pharma will actively promote the digital and
physical business layout in the pharmaceutical and healthcare
industry and is committed to becoming a first-class enterprise in
the global medical and health market.
For more information, please visit our official website:
www.fosunpharma.com
Forward Looking Statement:
This press release contains a Forward Looking Statement.
In addition to the historical factual statements contained in
this press release, all the discussions, including but not limited
to, discussions of our company's business strategy, discussions of
future operations, profit margins, profitability, liquidity and
capital resources, prospects for future development of our
company's industry and future development of the economy in general
in major markets, and any similar words or representations relating
to our company or its management, whether before, after or
including such words or representations as "expect", "seek",
"believe", "plan", "intend", "estimate", "project", "expect", "may"
and "will", are intended to identify forward-looking statements.
These statements are subject to certain known and unknown risks,
uncertainties and assumptions that may cause the actual results,
performance or achievements of our company to differ materially
from any future results, performance or achievements expressed or
implied by these forward-looking statements. Therefore, you should
not rely excessively on any forward-looking materials. Subject to
the requirements of applicable laws, rules and regulations, our
company has no obligation to update or otherwise modify the
forward-looking statement in this press release, whether as a
result of new information, future events or developments or
otherwise. In this press release, the statements or references to
our company's intentions are effective as of the date of this press
release. Any such intention may change with future developments.
All the forward-looking statements contained in this press release
are subject to the above cautionary statement.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fosun-pharma-announces-2022-annual-results-achieved-steady-growth-with-revenue-from-record-high-innovative-products-and-global-commercialization-capability-improvement-301783100.html
SOURCE Fosun Pharma